<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00805467</url>
  </required_header>
  <id_info>
    <org_study_id>C-935788-012</org_study_id>
    <secondary_id>D4300C00021</secondary_id>
    <nct_id>NCT00805467</nct_id>
  </id_info>
  <brief_title>Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies</brief_title>
  <official_title>An Open-Label, Multicenter Extension Study to Evaluate the Safety of R935788 in Patients With Rheumatoid Arthritis Who Have Completed the Treatment Phase of a Rigel-Sponsored R935788 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this new research study is to gain additional information about how safe and
      effective R935788 is over a longer period of time.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to
    Rigel Pharmaceuticals.
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Who Had at Least 1 Treatment Emergent Adverse Event in Any Category</measure>
    <time_frame>Entry in extension to end of study, up to a maximum of 5 years. (Variable by subject - median duration of 3 years)</time_frame>
    <description>AE = adverse event, bid = twice daily, IP = investigational product, qd = once daily, SAE = serious adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DAS28-CRP Score</measure>
    <time_frame>3 years</time_frame>
    <description>The Disease Activity Score 28 using C-Reactive Protein (DAS28-CRP) is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). These measures are then fed into a complex mathematical formula to produce the overall DAS on a scale from 1 to 10, where scores greater than 5.1 are considered to indicate active disease, scores less than 3.2 are considered to indicate with well controlled disease, and scores less than 2.6 are considered to indicate remission. bid = twice daily, CRP = C-reactive protein, DAS28 = Disease Activity Score based on a 28 joint count, n/a = not applicable, qd = once daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAQ-DI Score</measure>
    <time_frame>3 years</time_frame>
    <description>Health Assessment Questionnaire - Disability Index, a measure of physical function. The HAQ-DI score is calculated by summing the category scores from 8 sub-categories (ie, scores for patient ability in dressing and grooming, rising, eating, walking, hygeine, reach, grip and common daily activities) and dividing by the number of categories completed. The HAQ-DI score takes values between 0 and 3, with a higher score indicating greater disability. A HAQ-DI response is a reduction from baseline in HAQ-DI greater than or equal to the minimally important difference (0.22). BID = twice daily, DMARD = disease-modifying anti-rheumatic drug, OR = odds ratio, PO = orally, QD = once a day.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">624</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R935788 50 mg tablet, orally, twice-a-day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R935788 100 mg tablet, orally, twice-a-day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R935788 100 mg tablet, orally, once-a-day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R935788 150 mg tablet, orally, once-a-day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib Disodium (R935788)</intervention_name>
    <description>50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>R935788</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must give written informed consent by signing an IRB/EC-approved Informed
             Consent Form (ICF) prior to admission to this study

          -  Patients who are being treated in Study C-788-006X

          -  Patients who completed Studies C-788-010 or C-788-011 and did not withdraw due to
             adverse events

          -  Patients who withdrew from Study C-788-010 at Month 4 or Month 5 because of a
             pre-defined lack of efficacy

          -  Females of childbearing potential must be fully informed of the potential for R788 to
             adversely affect the fetus and, if sexually active, must agree to use a well
             established method of birth control during the study (oral contraceptive, mechanical
             barrier, long acting hormonal agent). These patients must not be lactating and must
             have a negative pregnancy test at the time of entry and at each laboratory
             determination.

        Exclusion Criteria:

          -  The patient has a history of, or a concurrent, clinically significant illness, medical
             condition (other than arthritis) or laboratory abnormality that, in the Investigator's
             opinion, could affect the conduct of the study. Specifically, excluded are patients
             with the following:

               1. unresolved Grade 2 or greater toxicity in a RA protocol studying R788

               2. uncontrolled or poorly controlled hypertension;

               3. recent (within past 2 months) serious surgery or infectious disease;

               4. recent history (since enrollment in prior R788 study) of, or treatment for, a
                  malignancy other than non-melanomatous skin cancer, or any history of lymphoma;

               5. known to be positive for Hepatitis B, Hepatitis C, HIV or Tuberculosis;

               6. interstitial pneumonitis or active pulmonary infection;

               7. known laboratory abnormalities: ALT &gt; 1.2 x ULN, creatinine &gt;1.5x ULN, an ANC
                  &lt;2,500/mm3 or 2.5 x 109/L, lymphocyte count &lt; 600/mm3 or 0.6 x 109L, Hgb &lt; 9 g/dL
                  or 5 mmol/L, platelet count &lt;125,000/mm3 or 125 x 109/L are excluded.

          -  The patient has a history of substance abuse, drug addiction or alcoholism. Patients
             may consume up to 4 units of alcohol per week; however, alcohol should be avoided in
             the 72 hours prior to lab assessments. Patients who cannot reliably comply with this
             should be excluded. A unit of alcohol is defined as the following: Beer = 12 oz or 355
             mL; wine = 5 oz or 148 mL; sweet dessert wine = 3 oz or 89 mL; 80 proof distilled
             spirits = 1.5 oz or 44 mL.

          -  The patient is unable to report for clinical and laboratory monitoring as per
             protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris O'Brien, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coeur D'Alene</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elizabethtown</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mayfiled Village</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cuernava</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Del. Cuauhtemoc</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leon</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexcio</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morelia</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Luis Potosí</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jesus Maria</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bytom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toruń</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zyrardów</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brailari</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sf. Gheorghe</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2008</study_first_submitted>
  <study_first_submitted_qc>December 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <results_first_submitted>January 22, 2014</results_first_submitted>
  <results_first_submitted_qc>May 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 25, 2014</results_first_posted>
  <last_update_submitted>May 23, 2014</last_update_submitted>
  <last_update_submitted_qc>May 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 624 patients were enrolled: 1, 59, 183 &amp; 381 were allocated to the 50mg twice daily (bid), 100 mg once daily (qd), 150 mg qd and 100 mg bid groups, respectively. As this was a long-term extension study no specific end date was given. Patients who were ongoing when the study was terminated are shown as completers.</recruitment_details>
      <pre_assignment_details>Treatments were assigned according to those given in the qualifying studies. All patients received investigational product.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fostamatinib 50 mg Bid</title>
          <description>Oral treatment</description>
        </group>
        <group group_id="P2">
          <title>Fostamatinib 100 mg qd</title>
          <description>Oral treatment</description>
        </group>
        <group group_id="P3">
          <title>Fostamatinib 150 mg qd</title>
          <description>Oral treatment</description>
        </group>
        <group group_id="P4">
          <title>Fostamatinib 100 mg Bid</title>
          <description>Oral treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1">Patients who received treatment</participants>
                <participants group_id="P2" count="59">Patients who received treatment</participants>
                <participants group_id="P3" count="183">Patients who received treatment</participants>
                <participants group_id="P4" count="381">Patients who received treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Enrolled But Did Not Receive Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1">Ongoing when study terminated</participants>
                <participants group_id="P2" count="25">Ongoing when study terminated</participants>
                <participants group_id="P3" count="80">Ongoing when study terminated</participants>
                <participants group_id="P4" count="144">Ongoing when study terminated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="103"/>
                <participants group_id="P4" count="237"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="86"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="50"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="57"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not reported</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fostamatinib 50 mg Bid</title>
          <description>Oral treatment</description>
        </group>
        <group group_id="B2">
          <title>Fostamatinib 100 mg qd</title>
          <description>Oral treatment</description>
        </group>
        <group group_id="B3">
          <title>Fostamatinib 150 mg qd</title>
          <description>Oral treatment</description>
        </group>
        <group group_id="B4">
          <title>Fostamatinib 100 mg Bid</title>
          <description>Oral treatment</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="183"/>
            <count group_id="B4" value="381"/>
            <count group_id="B5" value="624"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70">Standard deviation cannot be defined for a single patient.</measurement>
                    <measurement group_id="B2" value="51.4" spread="11.15"/>
                    <measurement group_id="B3" value="51.7" spread="13.32"/>
                    <measurement group_id="B4" value="53.8" spread="12.36"/>
                    <measurement group_id="B5" value="53.0" spread="12.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="157"/>
                    <measurement group_id="B4" value="324"/>
                    <measurement group_id="B5" value="535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="184"/>
                    <measurement group_id="B5" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="179"/>
                    <measurement group_id="B5" value="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Who Had at Least 1 Treatment Emergent Adverse Event in Any Category</title>
        <description>AE = adverse event, bid = twice daily, IP = investigational product, qd = once daily, SAE = serious adverse event</description>
        <time_frame>Entry in extension to end of study, up to a maximum of 5 years. (Variable by subject - median duration of 3 years)</time_frame>
        <population>The full analysis set includes those patients who received at least 1 dose of investigational product, and were summarised according to treatment first received in this study (intention-to-treat principle).</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 50 mg Bid</title>
            <description>Oral treatment</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg qd</title>
            <description>Oral treatment</description>
          </group>
          <group group_id="O3">
            <title>Fostamatinib 150 mg qd</title>
            <description>Oral treatment</description>
          </group>
          <group group_id="O4">
            <title>Fostamatinib 100 mg Bid</title>
            <description>Oral treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Had at Least 1 Treatment Emergent Adverse Event in Any Category</title>
          <description>AE = adverse event, bid = twice daily, IP = investigational product, qd = once daily, SAE = serious adverse event</description>
          <population>The full analysis set includes those patients who received at least 1 dose of investigational product, and were summarised according to treatment first received in this study (intention-to-treat principle).</population>
          <units>% of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="183"/>
                <count group_id="O4" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="91.5"/>
                    <measurement group_id="O3" value="90.7"/>
                    <measurement group_id="O4" value="88.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fatal AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="3.8"/>
                    <measurement group_id="O4" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE (including fatal AEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="18.6"/>
                    <measurement group_id="O4" value="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE leading to termination of study therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="22.0"/>
                    <measurement group_id="O3" value="16.4"/>
                    <measurement group_id="O4" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DAS28-CRP Score</title>
        <description>The Disease Activity Score 28 using C-Reactive Protein (DAS28-CRP) is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). These measures are then fed into a complex mathematical formula to produce the overall DAS on a scale from 1 to 10, where scores greater than 5.1 are considered to indicate active disease, scores less than 3.2 are considered to indicate with well controlled disease, and scores less than 2.6 are considered to indicate remission. bid = twice daily, CRP = C-reactive protein, DAS28 = Disease Activity Score based on a 28 joint count, n/a = not applicable, qd = once daily</description>
        <time_frame>3 years</time_frame>
        <population>Number of participants are those with baseline data. Baseline defined at entry into qualifying study or at entry into this study if more than 14 days since last dose in qualifying study. As no imputation was applied, the numbers at subsequent visits are lower.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 50 mg Bid</title>
            <description>Oral treatment</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg qd</title>
            <description>Oral treatment</description>
          </group>
          <group group_id="O3">
            <title>Fostamatinib 150 mg qd</title>
            <description>Oral treatment</description>
          </group>
          <group group_id="O4">
            <title>Fostamatinib 100 mg Bid</title>
            <description>Oral treatment</description>
          </group>
        </group_list>
        <measure>
          <title>DAS28-CRP Score</title>
          <description>The Disease Activity Score 28 using C-Reactive Protein (DAS28-CRP) is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). These measures are then fed into a complex mathematical formula to produce the overall DAS on a scale from 1 to 10, where scores greater than 5.1 are considered to indicate active disease, scores less than 3.2 are considered to indicate with well controlled disease, and scores less than 2.6 are considered to indicate remission. bid = twice daily, CRP = C-reactive protein, DAS28 = Disease Activity Score based on a 28 joint count, n/a = not applicable, qd = once daily</description>
          <population>Number of participants are those with baseline data. Baseline defined at entry into qualifying study or at entry into this study if more than 14 days since last dose in qualifying study. As no imputation was applied, the numbers at subsequent visits are lower.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="181"/>
                <count group_id="O4" value="374"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=1, 55, 181, 374)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.27">Standard deviation cannot be defined for a single patient.</measurement>
                    <measurement group_id="O2" value="5.34" spread="1.123"/>
                    <measurement group_id="O3" value="5.31" spread="1.162"/>
                    <measurement group_id="O4" value="5.36" spread="1.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quarter 4 (n=1, 41, 136, 254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00">Standard deviation cannot be defined for a single patient.</measurement>
                    <measurement group_id="O2" value="3.57" spread="1.408"/>
                    <measurement group_id="O3" value="3.46" spread="1.282"/>
                    <measurement group_id="O4" value="3.44" spread="1.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quarter 8 (n=1, 33, 114, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92">Standard deviation cannot be defined for a single patient.</measurement>
                    <measurement group_id="O2" value="3.43" spread="1.412"/>
                    <measurement group_id="O3" value="3.25" spread="1.290"/>
                    <measurement group_id="O4" value="3.35" spread="1.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quarter 12 (n=1, 30, 94, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31">Standard deviation cannot be defined for a single patient.</measurement>
                    <measurement group_id="O2" value="3.36" spread="1.376"/>
                    <measurement group_id="O3" value="3.07" spread="1.055"/>
                    <measurement group_id="O4" value="3.27" spread="1.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HAQ-DI Score</title>
        <description>Health Assessment Questionnaire - Disability Index, a measure of physical function. The HAQ-DI score is calculated by summing the category scores from 8 sub-categories (ie, scores for patient ability in dressing and grooming, rising, eating, walking, hygeine, reach, grip and common daily activities) and dividing by the number of categories completed. The HAQ-DI score takes values between 0 and 3, with a higher score indicating greater disability. A HAQ-DI response is a reduction from baseline in HAQ-DI greater than or equal to the minimally important difference (0.22). BID = twice daily, DMARD = disease-modifying anti-rheumatic drug, OR = odds ratio, PO = orally, QD = once a day.</description>
        <time_frame>3 years</time_frame>
        <population>Number of participants are those with baseline data. Baseline defined at entry into qualifying study or at entry into this study if more than 14 days since last dose in qualifying study. As no imputation was applied, the numbers at subsequent visits are lower.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 50 mg Bid</title>
            <description>Oral treatment</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg qd</title>
            <description>Oral treatment</description>
          </group>
          <group group_id="O3">
            <title>Fostamatinib 150 mg qd</title>
            <description>Oral treatment</description>
          </group>
          <group group_id="O4">
            <title>Fostamatinib 100 mg Bid</title>
            <description>Oral treatment</description>
          </group>
        </group_list>
        <measure>
          <title>HAQ-DI Score</title>
          <description>Health Assessment Questionnaire - Disability Index, a measure of physical function. The HAQ-DI score is calculated by summing the category scores from 8 sub-categories (ie, scores for patient ability in dressing and grooming, rising, eating, walking, hygeine, reach, grip and common daily activities) and dividing by the number of categories completed. The HAQ-DI score takes values between 0 and 3, with a higher score indicating greater disability. A HAQ-DI response is a reduction from baseline in HAQ-DI greater than or equal to the minimally important difference (0.22). BID = twice daily, DMARD = disease-modifying anti-rheumatic drug, OR = odds ratio, PO = orally, QD = once a day.</description>
          <population>Number of participants are those with baseline data. Baseline defined at entry into qualifying study or at entry into this study if more than 14 days since last dose in qualifying study. As no imputation was applied, the numbers at subsequent visits are lower.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="181"/>
                <count group_id="O4" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=1, 56, 181, 376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25">Standard deviation cannot be defined for a single patient</measurement>
                    <measurement group_id="O2" value="1.50" spread="0.735"/>
                    <measurement group_id="O3" value="1.46" spread="0.707"/>
                    <measurement group_id="O4" value="1.46" spread="0.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quarter 4 (n=1, 41, 138, 254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57">Standard deviation cannot be defined for a single patient</measurement>
                    <measurement group_id="O2" value="1.00" spread="0.677"/>
                    <measurement group_id="O3" value="1.07" spread="0.726"/>
                    <measurement group_id="O4" value="0.99" spread="0.722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quarter 8 (n=1, 33, 107, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43">Standard deviation cannot be defined for a single patient</measurement>
                    <measurement group_id="O2" value="1.00" spread="0.657"/>
                    <measurement group_id="O3" value="1.02" spread="0.720"/>
                    <measurement group_id="O4" value="0.95" spread="0.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quarter 12 (n=1, 30, 94, 176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38">Standard deviation cannot be defined for a single patient</measurement>
                    <measurement group_id="O2" value="1.01" spread="0.651"/>
                    <measurement group_id="O3" value="0.98" spread="0.718"/>
                    <measurement group_id="O4" value="0.96" spread="0.687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>100 MG BID</title>
        </group>
        <group group_id="E2">
          <title>100 MG QD</title>
        </group>
        <group group_id="E3">
          <title>150 MG QD</title>
        </group>
        <group group_id="E4">
          <title>50 MG BID</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>THROMBOTIC THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIOSPASM CORONARY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>INTRACARDIAC THROMBUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>GOITRE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>PANOPHTHALMITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>COLITIS MICROSCOPIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>COLONIC POLYP</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>FAECALOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>GASTRIC PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>HIATUS HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PANCREATITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>RECTAL PROLAPSE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>DEVICE DISLOCATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS SOFT TISSUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>BURSITIS INFECTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS HEPATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>DYSENTERY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>EPIGLOTTITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>ERYTHEMA MIGRANS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>GIARDIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>INFECTED BITES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>MENINGITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>NECROTISING FASCIITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>VARICELLA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>DISLOCATION OF VERTEBRA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>MUSCLE RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PUBIS FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>CERVICAL SPINAL STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>MYOSITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ANAL CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>BASOSQUAMOUS CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>BRAIN NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>CERVIX CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>COLON CANCER STAGE IV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>DIFFUSE LARGE B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PARATHYROID TUMOUR BENIGN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>THYROID CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE POLYNEUROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>LUMBAR RADICULOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>RADICULOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>ABORTION SPONTANEOUS INCOMPLETE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ENDOMETRIAL HYPERTROPHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>POSTMENOPAUSAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>VAGINAL PROLAPSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>LUNG INFILTRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>HIP ARTHROPLASTY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>IMPLANTABLE DEFIBRILLATOR INSERTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>KNEE ARTHROPLASTY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="306" subjects_at_risk="381"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="141" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="381"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" events="17" subjects_affected="13" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="34" subjects_affected="30" subjects_at_risk="381"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="381"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="381"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="151" subjects_affected="96" subjects_at_risk="381"/>
                <counts group_id="E2" events="36" subjects_affected="20" subjects_at_risk="59"/>
                <counts group_id="E3" events="93" subjects_affected="60" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="381"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="381"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="381"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="381"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="381"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="34" subjects_affected="24" subjects_at_risk="381"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="38" subjects_affected="26" subjects_at_risk="381"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" events="20" subjects_affected="14" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="54" subjects_affected="36" subjects_at_risk="381"/>
                <counts group_id="E2" events="15" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E3" events="20" subjects_affected="18" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="381"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="381"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="37" subjects_affected="26" subjects_at_risk="381"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="76" subjects_affected="51" subjects_at_risk="381"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E3" events="29" subjects_affected="20" subjects_at_risk="183"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="125" subjects_affected="72" subjects_at_risk="381"/>
                <counts group_id="E2" events="32" subjects_affected="12" subjects_at_risk="59"/>
                <counts group_id="E3" events="45" subjects_affected="28" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" events="35" subjects_affected="27" subjects_at_risk="381"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" events="45" subjects_affected="35" subjects_at_risk="381"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERLIPIDAEMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="381"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="25" subjects_affected="17" subjects_at_risk="381"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" events="16" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="35" subjects_affected="30" subjects_at_risk="381"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="381"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="381"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" events="69" subjects_affected="38" subjects_at_risk="381"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" events="16" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>TENDONITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="49" subjects_affected="33" subjects_at_risk="381"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E3" events="35" subjects_affected="23" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTONIC BLADDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="381"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="381"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>SKIN LESION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="82" subjects_affected="62" subjects_at_risk="381"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="59"/>
                <counts group_id="E3" events="31" subjects_affected="26" subjects_at_risk="183"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dave Goldstraw</name_or_title>
      <organization>AstraZeneca Pharmaceuticals</organization>
      <phone>+44 (0)1625 512415</phone>
      <email>dave.goldstraw@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

